Maximum quantity allowed is 999
Please select the quantity
CAS RN: 284461-73-0 | Product Number: O0599
Sorafenib
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- BAY 43-9006
- 4-[4-[3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido]phenoxy]-N-methylpicolinamide
Product Documents:
| Size | Unit Price | Shanghai | Tianjin | Japan* |
|---|---|---|---|---|
| 500MG |
¥160.00
|
2 | 1 | 36 |
* For order or inquiry, please contact
Our Authorized Distributors.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
* To send your quote request for bulk quantities, please click on the "Request Bulk Quote" button. Please note that we cannot offer bulk quantities for some products.
| Product Number | O0599 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__1H__1__6ClF__3N__4O__3 = 464.83 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Refrigerated (0-10°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Air Sensitive,Heat Sensitive |
| Packaging and Container | 500MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 284461-73-0 |
| Reaxys Registry Number | 9666200 |
| MDL Number | MFCD06411450 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Volumetric Analysis) | min. 98.0 % |
| Melting point | 203.0 to 207.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 205 °C |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H360 : May damage fertility or the unborn child. H362 : May cause harm to breast-fed children. H372 : Causes damage to organs through prolonged or repeated exposure. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy/ while nursing. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
Related Laws:
| RTECS# | US4588870 |
Transport Information:
| Customs Control Conditions (Q) |
Application
Sorafenib: An Inhibitor of Multiple Protein Kinases
The Ras/Raf/MEK/ERK signaling pathway is an important mediator of tumor cell proliferation and angiogenesis. Sorafenib (BAY 43-9006) inhibits intracellular Raf kinases (C-Raf, B-Raf and mutant B-Raf) and cell surface receptor tyrosine kinases (c-KIT, FLT- 3, RET, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR).1-4) Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. In fact, sorafenib decreases tumor cell proliferation and angiogenesis in vitro. There are reports, that sorafenib also inhibits LRRK2 (Leucine-rich repeat kinase 2) –G2019S that is a promising therapeutic target for the treatment of Parkinson's disease.5) (The product is for research purpose only.)
References
- 1) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
- 2) Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5
- 3) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer (a review)
- 4) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling (a review)
- 5) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease
Articles/Brochures
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.
Other Documents
Related Products
![Sorafenib [Optimized for Cell Culture]](/medias/Tci-300-O0672.jpg?context=bWFzdGVyfHJvb3R8OTI4MnxpbWFnZS9qcGVnfGFEZGhMMmd6T0M4NU5EZzRPRGt6TURVd09URXdMMVJqYVMwek1EQmZUekEyTnpJdWFuQm58MWVkNTVhYmIyMjYxNTU3Y2E0NmUxOTE4NDA0MWM4NzQzOWViYjkwMGVhMWVlYmMzOGFjYmMxMmEyMzQ4MjNiMg "Sorafenib [Optimized for Cell Culture]")
Sorafenib [Optimized for Cell Culture]
| Product # | O0672 |
| CAS RN | 284461-73-0 |
| Purity / Analysis Method: |